Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308599 | 0.83 | GRM5 (0.44) | GRM5CSNK1ECSNK1DPTGDR2KCNK3 | |
| SCHEMBL3108073 | 0.80 | GRM5 (0.43) | GRM5CSNK1DPTGDR2KCNK3KDM1A | |
| SCHEMBL29308604 | 0.80 | TRPC3 (0.39) | GRM5CSNK1ECSNK1DPTGDR2F2 | |
| SCHEMBL29308606 | 0.80 | CSNK1D (0.40) | GRM5CSNK1ECSNK1DPTGDR2F2 | |
| SCHEMBL24348526 | 0.77 | GRM5 (0.43) | GRM5PTGDR2F2F12CYP2C19 | |
| SCHEMBL13254961 | 0.76 | MAPK14 (0.45) | CSNK1ECSNK1D | |
| SCHEMBL19998108 | 0.72 | THRB (0.45) | CSNK1ECSNK1DKCNK3KMT2ANPSR1 | |
| SCHEMBL20400623 | 0.72 | DHFR (0.48) | GRM5F2F12CYP2C19SMN1; SMN2 | |
| SCHEMBL26969090 | 0.72 | MEN1 (0.45) | GRM5PTGDR2F2F12CYP2C19 | |
| SCHEMBL26969129 | 0.71 | MEN1 (0.44) | F2F12CYP2C19SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | GRM5 757/4885CSNK1E 1569/4885CSNK1D 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.